Sexually Transmitted Diseases (STDs) Treatment Market Explore Future Growth by Global Top Players - Merck & Co. Inc., Pfizer INC, GlaxoSmithKline Plc, Vertex Pharmaceuticals, Roche, Gilead Sciences Inc., Johnson & Johnson, and Bristol-Myers Squibb

Sexually transmitted disease also known as venereal diseases is a clinical syndrome of infection, acquired and transmitted through sexual activity via body fluids such as semen, vaginal fluid or blood. The causative agent of STD are bacteria, parasites, yeast, and viruses. Symptoms of STDs include skin rashes, warts, abdominal pain or genital ulcers. STDs are detected by physical examination or assays such as ELISA (Enzyme-Linked Immunosorbent Assay), rapid plasma reagin blood test or antibody-absorption blood test. The sexually transmitted disease treatment market is expected to witness high growth in the forecast period (2017 – 2025), due to the factors such as increasing disease burden, governmental initiatives for increasing awareness, growing diagnosis of sexually transmitted diseases, and increasing number of pipeline products by manufacturers for treatment of these diseases.

Download PDF Brochure of Research Report @ https://www.coherentmarketinsights.com/insight/request-pdf/2005

Sexually Transmitted Diseases Treatment market – Driver

Increasing sexually transmitted disease burden is fueling the growth of the STDs treatment market. Among 20 STDs, the most common are Gonorrhea, Chlamydia, Syphilis, Herpes, Hepatitis (HBV), and Human Immunodeficiency Virus (HIV). For instance, according to Centers for Disease Control and Prevention (CDC), in the year 2016, 1,598,354 cases of Chlamydia trachomatis infection were reported in the U.S., corresponding to 497.3 cases per 100,000 in 2015. Furthermore, 468,514 gonorrhea cases were reported for a rate of 145.8 cases per 100,000 population, an increase of 18.5% from 2015. This increasing incidence of STDs is also due to the unprotected sexual practice, which in turn fueled demand for STDs treatment. For instance, according to the World Health Organization (WHO), unsafe sex is the second most common risk factor for increasing disease burden.

The number of products in the pipeline for HIV treatment are high, which is expected to propel the growth of the sexually transmitted disease treatment market. For instance, in 2017, GSK and ViiV Healthcare applied in European Medicines Agency (EMA) and US Food and Drug Administration (FDA), for regulatory affiliation for a single-tablet, the two-drug regimen of dolutegravir (by ViiV Healthcare) and rilpivirine (by Janssen) used for the treatment of HIV-1 infection. Moreover, other drug candidates in the pipeline include – PrEP, PRO140 with ibalizumab, BMS- 955176, which are expected to be launched in the forecast period. Moreover, governments are focusing on funding research and development programs, which is expected to aid in the growth of the market. For instance, British Columbia Center for Disease Control sponsored doxycycline (drug) studies for indication of syphilis and other sexually transmitted infection, which is in early phase I clinical trial as of 2016.

Sexually Transmitted Diseases Treatment market – Competitor

Major players in highly fragmented sexually transmitted diseases treatment market are Merck & Co. Inc., Pfizer INC, GlaxoSmithKline Plc, Vertex Pharmaceuticals, Roche, Gilead Sciences Inc., AbbVie Inc., Johnson & Johnson, and Bristol-Myers Squibb. Key players in the sexually transmitted disease treatment market are focusing on adopting strategies such as mergers and collaborations for expanding their research for candidate drugs. For instance, in 2017, the drug Zoloflodacin entered into clinical trials, as a result of the partnership between Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics. Moreover, in March 2018, Inovio Pharmaceuticals, Inc. entered into a deal with ApolloBio Corp., which have the exclusive rights for development, manufacturing, and commercialization of VGX – 3100, Inovio’s DNA immunotherapy product for pre-cancer indication.

Request For Customization of Research Report @ https://www.coherentmarketinsights.com/insight/request-customization/2005

Sexually Transmitted Diseases Treatment market - Taxonomy

By Disease Type:

Gonorrhea
Chlamydia
Syphilis
Herpes
Hepatitis (HBV)
Human Immunodeficiency Virus (HIV)
Other Indications

By Therapy Type:

Anti-bacterial drugs
Anti-viral drugs
Anti-fungal drugs

By Route of Administration:

Oral
Injectable
Topical

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.